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Introduction
Research has resulted in major improvements in health-
care in the past 50 years. Advances in the field of
genomics/genetics are anticipated to lead to further accel-
eration in the progress of research development, with the
promise of a new era for diagnosis, treatment and preven-
tion of disease. But despite spectacular progress in medi-
cine and general improvement of health across the world,
cardiovascular diseases remain a global problem, and
coronary heart disease (CHD) in particular is anticipated
to be a problem over the next 30 years, both for the devel-
oped and developing world.
Retrospective analysis of health and social problems illus-
trates limited success in identifying and dealing with
potentially preventable health problems. Recent conclu-
sions from the European Action on Secondary Prevention
through Intervention to Reduce Events (EUROASPIRE) II
[1] drawn by Wood, who coordinated the study, are rele-
vant here. Among the many disappointing results was the
fact that 81% of the individuals surveyed in 1999/2000
were overweight, with a third of them obese. The propor-
tion of obese people increased sharply from 25% in
1995/96, while the number of smokers was unchanged,
despite anti-smoking campaigns. Further, 61% of those
surveyed had hypertension and 59% had abnormally high
cholesterol, despite increased use of antihypertensive and
cholesterol lowering drug treatment. Wood argued that
the findings revealed “inadequate standard of care” and “a
collective failure of the medical practice.” He claimed that
cardiologists are too focused on acute management and
are paying insufficient attention to prevention and long-
term treatment.
The multifaceted clinical complexity of CHD, with a bias
towards acute treatment, neglect of preventive care, and
inappropriate long-term treatment of patients after acute
coronary events, requires fundamental reform to improve
patients` outcomes and quality of life, as well as the cost-
effectiveness of treatment. Future preventive measures
need to focus on establishing risk factor profiles in individ-
ual patients, accurately identifying those at risk, and actively
intervening to maximize the ability to change that risk. More-
over, prevention strategies need to begin in childhood.
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Public health impact of CHD
Despite declining mortality rates from cardiovascular
disease during the past three decades, cardiovascular dis-
orders still account for the highest mortality rates both in
developed and in developing countries. Coronary heart
diseases are in turn the most prevalent of the cardiovascu-
lar disorders, accounting for 6.3 million deaths in 1990, at
a time when a steady decline in heart disease mortality
was stated to be ongoing [2].
CHD remains a massive public health problem in the
developed world, both for survival and for work capacity.
In the USA alone, more than 10 million individuals have
symptomatic CHD, resulting each year in approximately
1.5 million myocardial infarctions, almost 1 million deaths,
and an economic burden of $12 billion. “CHD is the single
largest killer of American males and females” [3].
In European countries, cardiovascular mortality represents
around 40% of all mortality before the age of 74. Despite
decreasing age-specific cardiovascular disease mortality
rates in Western European countries, there has been no
decrease in the absolute number of people who die from
cardiovascular diseases. The number of chronically ill car-
diovascular patients may even be increasing in these
countries due to the ageing of the population. Because of
a fall in early mortality, currently available treatments for
diseases such as acute myocardial infarction may lead to
an increase in the number of patients who reinfarct and
the number with congestive heart failure. For this reason,
and because of the increasing trend in cardiovascular
mortality in Central and Eastern European countries, the
burden of cardiovascular diseases in European societies
will not decrease and may even increase in the forthcom-
ing decades [4].
Despite national and international guidance, evidence of
clinical effectiveness, and widespread agreement on man-
agement of risk factors, primary prevention of CHD is
inadequate and remains underdeveloped and under-
funded [5,6].
The joint European Task Force set up in 1998 has empha-
sized the need for national guidelines to establish a
“model for care” for preventive cardiology and for promo-
tion of greater collaboration between hospitals and
primary care. Representatives from the European Society
of Cardiology, European Atherosclerosis Society, Interna-
tional Society of Behavioral Medicine, European Society of
General Practice/Family Medicine, and from the European
Heart Network underlined the concern that Europe is not
capitalizing upon the extensive life-saving potential of pre-
ventive cardiology [7]. The task force proposals are focus-
ing upon the need that each country should draw up its
own model of care with the aim of implementing routine
screening for cardiovascular disease, medical record
keeping, systematic follow-up of patients, and coronary
risk management.
This paper will attempt to draw attention to different
factors encountered in daily practice that may potentially
have a negative impact on the provision of long-term care
to patients with CHD and, particularly, on the primary pre-
vention of CHD in the general population.
The author proposes a paradigm shift in the approach to
primary and secondary prevention of CHD, with their inte-
gration into a common management strategy for the differ-
ent stages of the same pathological entity: the coronary
heart disease.
Barriers in the implementation of preventive
strategies
Surveys of CHD prevention-related services such as
smoking cessations advice, measurement and treatment
of lipid disorders, and physical activity assessment and
counseling are disappointing [8–12]. Significant variation
exists among the risk control therapies of patients with
cardiovascular diseases. Major drugs in the cardiovascular
therapy arsenal such as beta-blockers, angiotensin-con-
verting enzyme inhibitors, aspirin, and lipid lowering drugs
are currently underused [13–15]. A variety of factors at
the levels of the patient, physician, health care setting and
community/society, as well as the lack of a third party
payment, may interfere with the provision of these services
(see Table 1 [14]).
Low physician adherence
In spite of international consensus guidelines and tremen-
dous amounts of health information surrounding CHD pre-
vention, it seems that substantial confusion perpetuates
among both physicians and their patients [16]. Unfortu-
nately, conflicting messages in different guidelines
[17–19] and inaccuracy in identifying high-risk patients
are often contributing factors [20].
It is generally assumed that physicians are aware of the
relative importance of the various risk factors for CHD.
However, the busy schedules of both primary care and
specialist clinicians, combined with defective training in
the field of disease prevention, and the lack of financial
incentives for prevention measures have combined to
produce very poor systematic prevention of CHD in clini-
cal practice [21,22].
Poor patient compliance
Nowadays we witness a rising interest in health, healthy
living, and healthy environment. Successful campaigns in
the field of ‘prevention and health promotion’ focusing on
hot topics such as smoking, alcohol consumption, and
high cholesterol have undoubtedly raised the level of
awareness of health issues in the general population.Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 1 Pater
However, closer scrutiny uncovers a poor compliance of
the general, still healthy population, with the need for
lifestyle changes and risk factor modification strategies.
This may simply be explained by the fact that people are
generally attracted by the prospect of a benefit which is
visible early, and which they can definitely gain from.
Health benefits rarely meet these criteria; they may be real,
but they are likely to be delayed and to come to only a few
of those who seek them. This phenomenon has been
called “prevention paradox” [23], meaning that preventive
measures that bring large benefits to the community offer
little to individual participants.
Lastly, there is a lack of structured and systematic informa-
tion on different treatments and decisions, which physi-
cians are supposed to give to their patients to help them
come to informed decisions about their healthcare. Failure
to provide patients with basic information such as the
potential risks and benefits of a certain therapy, the incon-
venience, the side effects, and the cost may result in the
rejection of a proposed therapy, instead of long-term
adherence to it. It should also be noted that individual
patients expect quite a lot, but carry too little responsibility
for their own actions or participation in decisions. Most
probably, the rights of individuals will increase in the next
decades, but so will the responsibility of individuals and
the acceptance of risk associated with medical decisions
agreed between physician and patient [24].
Lack of third party payment
Medical thinking has been largely concerned with
responding to the need of the sick individual. This has
shaped its ethics (responsibility for the sick), its research
(why do individuals become sick?), and the planning of
medical services. A disease-oriented model of healthcare
has emerged, with highest priority given to the prevention
of death and acute illness. This reflects the particular
outlook common to both doctors and healthcare policy
makers of viewing ill health through a dichotomous para-
digm of yes/no decisions, such as to investigate or not to
investigate, to admit or to send home, to treat or not to
treat, with the ultimate aim of reducing the number of
people requiring medical care in order to cut cost.
This type of reasoning struggles to achieve the defined
purpose-triad of medicine: to prevent occurrence of
disease, to prolong life, and to improve quality of life by
minimizing unwanted symptoms.
In an era of cost consciousness, there are increasingly
demands that health promotion and disease prevention
programs be proven economically worthwhile by means of
cost-effectiveness analysis. People generally agree that it
is worth investing in health promotion activities; however,
it is difficult to prove that the value of benefits obtained
outweigh the cost of those investments or that they, at
least, equal the clear benefits obtained from managing
medical emergencies and waiting lists, both being
focused by policy makers [25,26]. The continuous
increase of the percentage of aging population demands
allocation of greater amount of resources.
Demographic changes
The progressive ageing of the population in the twentieth
century, caused by unprecedented gains in life
expectancy, offers not only great opportunities but also
formidable challenges for all societies. The global popula-
tion of people over the age of 65 is increasing by 750,000
a month. Increases in the older population of up to 300%
are expected in many developing countries within the next
30 years [27].
Another demographic feature that makes the process of
ageing much more complicated is the fact that, in the next
25 years, while the population aged 65 years and above is
likely to grow by 88%, the working-age population will
increase by only 45%. The direct consequence of this fact
is that a steadily declining number of people of productive
age will have to provide for an expanding number of
dependants, in the form of direct support to older relatives
and through escalating taxation to cover the provision of
health and social services [28–30].
Table 1
Barriers to Implementation of Preventive Services
Patient
Lack of knowledge and motivation
Lack of access to care
Cultural factors
Social factors
Physician
Problem-based focus
Feedback on prevention is native or neutral
Time constraints
Lack of incentives, including reimbursement
Lack of training
Poor knowledge of benefits
Perceived ineffectiveness
Lack of skills
Lack of specialist–generalist communication
Lack of perceived legitimacy
Health care settings (hospitals, practices, etc)
Acute care priority
Lack of resources and facilities
Lack of systems for preventive services
Time and economic constraints
Poor communication between specialty and primary care providers
Lack of policies and standards
Community/society
Lack of policies and standards
Lack of reimbursement
Data from Pearson et al [94].Population ageing is beginning to transform health care
and social systems, with new public policies in health and
social care being widely adopted throughout the world
[31]. Public interest and discussion of healthcare issues is
at an all-time high. Because of the cost of healthcare,
which is continually escalating both in developed and
developing countries, there is a widespread trend toward
structural reform of healthcare systems [32].
Nowadays, there is a growing discrepancy between what
is possible in modern healthcare provision and what is
affordable within limited budgets. Perverse incentives,
which are inherent to all healthcare systems, result in inef-
fective and inefficient delivery of care. A competitive
healthcare market with the separation of purchasers and
providers has been introduced in several Western coun-
tries as a means of increasing the efficiency of healthcare
provision. A common feature is that health authorities, hos-
pital administrators, and providers are looking for addi-
tional means of financing through raised patient
copayments and private insurance.
The impact of IT on healthcare
It is apparent that the development and diffusion of effec-
tive medical technology must not be limited, and that a
well-organized assessment capability in close collabora-
tion between physicians and health care insurers should
be developed, if we want to maintain delivery and access
to high quality care in the future [33].
This concrete strategy for change calls for joint invest-
ment by government and industry into healthcare infra-
structure, applications for healthcare information systems,
and the development of the pre-requisite technology for
these applications.
New practice paradigms and administrative functions
should be targeted for strategic investment in order to
enhance the development of new medical practice para-
digms that incorporate a trend towards patient-centered
healthcare, including a focus on wellness, prevention pro-
grams, and evidence-based healthcare.
Implementing community-wide networks for healthcare
information will lead to the development of information
systems that allow clinical and administrative data to be
readily accessed, regardless of location, with appropriate
safeguards for protecting patient confidentiality, and in a
manner convenient for practitioners and patients.
Integrated vision of primary and secondary
prevention of CHD
Increasingly sensitive technologies that can identify patho-
physiologic states, early lesions, or silent disease in
persons who have never been symptomatic have permit-
ted an expanded definition of health that extends far
beyond ‘absence of disease’ and emphasizes the need for
prevention of disease occurrence. Despite the large
overlap of the primary and secondary prevention of CHD,
the first can be defined as the prevention of the athero-
sclerotic process itself, with the latter being the treatment
of the atherosclerotic disease process [35].
Since the risk factors concept was introduced in 1948 by
the Framingham Study investigators, tens of risk factors
have been suggested as determinants of CHD. Several
modifiable, or behavioral, risk factors (cigarette smoking,
poor diet, hypercholesterolemia, excessive alcohol intake,
lack of exercise) have been shown to be causally related
to CHD [36–38], and these may be approached either on
a population-wide or an individual basis. Nonmodifiable
factors, such as age, sex, race and family history of CHD,
may be used to identify high-risk groups of individuals who
would benefit from specific programs. Additional factors
termed physiological, such as hypertension, diabetes,
obesity and different types of dyslipidemias, interact with
the nonmodifiable and behavioural risk factors, leading to
the clinical manifestations of atheroclerosis: coronary
heart disease, hypertensive heart disease, thrombotic or
hemorrhagic stroke and peripheral vascular disease
(Fig. 1) [39].
During the past 5 decades, and in particular during the
past 10 years, we not only accumulated knowledge on risk
factors and CHD pathophysiology, we also witnessed a
continual metamorphosis of recommendations and guide-
lines for prevention and treatment of coronary heart
disease. Nevertheless, during the first years of the last
decade, individual risk factors such as raised blood pres-
sure and high cholesterol were focused on by separate
guidelines, which recommended treatment on the basis of
specified cut-off points. Not only that, but professional
societies both in the US and in Europe had separate
guidelines on coronary prevention [40], hyperlipidemia
[41,42], hypertension [43], and diabetes [44]. However,
there is nowadays a universal consensus as to similar
management of the modifiable risk factors in the context of
both primary and secondary prevention of CHD (Table 2).
In 1989 Rose described two approaches for the practical
management of risk factors [22]: the ‘population
approach’ and the ‘high risk approach’. The recommenda-
tion of combining both approaches in clinical practice is
based on reasoning from epidemiological explanations of
the risk factor distribution in populations.
The bell-shaped distribution of values (Fig. 2) of a particu-
lar risk factor, (eg cholesterol) suggests that most people
are found in its middle part and have cholesterol levels
around the average. However, one tail of the distribution
contains individuals with higher values. A more concrete
example is reflected by Fig. 3, which has been assembled
Available online http://cvm.controlled-trials.com/content/2/1/024
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[89]. The bar diagram presents the distribution of serum
cholesterol levels, with the commonest values being
around 5–5.5 mmol/l. The broken curve shows that the
incidence of fatal heart attacks rises steeply with increas-
ing levels of cholesterol. At the highest level (8 mmol/l) 20
deaths per 1000 individuals are registered, although the
prevalence of such exposure is only 2%.
Persons with risk levels in the tail of a distribution are a
deviant high-risk minority. They qualify for special attention
and are the target of high-risk preventive strategy, which
normally takes place when the physician is treating a
patient for ailments such as hypertension or high choles-
terol. With this approach, the remaining individuals in the
population are classified as normal and can be left in
peace. However, while the rate of cardiovascular disease
is higher in the high-risk individuals, they only account for a
small percentage of those who suffer from the disease.
Most cases of CHD occur among those falling in the
average risk group, classified as normal. The ‘population
approach’ is concerned with this latter group and the
reduction of the population burden of CHD that may result
from shifting the entire population level of risk factors (the
dashed bell-shaped curve, Fig. 2).
The population and high-risk approaches are not mutually
exclusive. They should be used in combination and consti-
tute one of the main pillars of any health policy. However,
the two approaches are somewhat different, primarily from
a logistic and organizational point of view.
The population approach proceeds from the basic axiom
that CHDs are epiphenomenona in populations that adopt
a Western lifestyle, characterized by high-fat and high-
cholesterol diet, tobacco use, and lack of physical activity.
It is therefore a matter of application of essential public
services such as surveillance, education, organizational
partnerships, assurance of personal health services, and
legislation/policy [90] in a variety of community settings
including work sites, healthcare facilities, religious organi-
zations, schools, and whole communities [91], with the
main goal of achieving reduced impact of risk factors and
risk behaviors on the health of the general population. Epi-
demiological evidence and results from clinical trials have
demonstrated that such goals are achievable in practice
[92].
Fig. 4 illustrates the specific means applicable in specific
community settings, with the aim of controlling risk factors
and risk behaviors on a population basis.
Individual risk assessment
Gradually, previous guidelines based on relative risk have
been replaced by joint American and European recom-
mendations and guidelines based on absolute measures
of risk [65]. The absolute risk of cardiovascular disease is
strongly influenced by the combination of risk factors
present, particularly a history of cardiovascular disease,
age, gender, diabetes, smoking, blood pressure, and
blood lipid concentrations [66]. The assessment of these
factors through careful history taking, physical examina-
tion, and selected laboratory testing is absolutely neces-
Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 1 Pater
Figure 1
Relationship between cardiovascular risk factors and cardiovascular diseases. HDL, high-density lipoprotein; LDL, low-density lipoprotein.sary for quantification of global risk score. Specific target
levels for particular risk factors are used to prioritize goals
for behavioral and pharmacological intervention (Table 3)
[93]. The new clinical guidelines recommend that priority
for treatment should be given to patients at high absolute
risk of coronary heart disease, defined as probability of
developing coronary heart disease over a specified period,
rather than emphasis being placed on an individual risk
factor [67].
Fig. 5 attempts to present CHD in its whole spectrum, as
a continuum in which the dichotomy of having or not
having an acute coronary event is only one level of the
same disease, which actually starts many years before the
occurrence of that acute event.
The Primary Prevention section in Fig. 5 summarizes the
distribution of high absolute risk (>20% probability of
developing CHD in the next 10 years) in the high risk (H)
group and part of the medium risk (M) group individuals.
The high absolute risk individuals may sustain acute coro-
nary events in their late thirties or early forties, depending
upon a multitude of factors that are difficult to predict. Indi-
viduals with relative risk corresponding to the low-risk
group and part of the medium risk group individuals in the
general population, run the risk of coronary events at a
later age, usually in their sixties or even later.
The risk of a coronary heart disease event (death, non-fatal
myocardial infarction, and angina) in 10 years has been
adopted as the standard measure in both Europe and the
Available online http://cvm.controlled-trials.com/content/2/1/024
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Table 2
Evidence base for benefit of risk factor modification
Risk factor Primary prevention of CHD Secondary prevention of CHD
Smoking Smoking cessation will reduce the risk of death by  Patients who continue to smoke after a myocardial infarction 
50% [45]. Men who stop smoking have a reduced risk  had a 22–47% increase in mortality risk [49]. In patients 
of myocardial infarction [46] and within 2–3 years the  followed up for 15 years, 82% mortality was seen in those 
risk is similar to those who have never smoked [47]. patients who continued to smoke after the first myocardial 
infarction or unstable angina. In patients who had stopped 
smoking, the figure was 37% [50].
Diet Dietary changes (reduction in saturated fat, cholesterol  There was a 29% reduction in 2-year all-cause mortality in 
and an increase in polyunsaturated fat) can result in  post-myocardial infarction patients who received advice on an 
decreased mortality from CHD [46,51]. The addition of  increase in fatty fish intake [53]. However the incidence of 
stanol esters and plant sterols (which reduce  re-infarction and CHD mortality was not significantly changed. 
cholesterol absorption) to food, for example margarine,  A Mediterranean-type diet (replacing red meat with poultry and 
has been shown to reduce plasma cholesterol  increasing fish, vegetables, fruit, and use of olive oil) in 
concentrations by about 10%. The effect equates with  myocardial infarction patients demonstrated a 76% reduction in 
a mortality risk reduction of about 23%; lack of control  the risk of CHD mortality.
over intake results in variable effects [52].
Cholesterol Total serum cholesterol of >6 mmol/l is associated with 
an increased incidence of CHD risk and risk of CHD 
mortality [54].
Exercise Lack of physical fitness or physical activity are associated 
with an increased risk of death from all causes and from 
cardiovascular disease both in middle-aged [55] and 
older men [56].
Alcohol Mortality from CHD is lowest in those who reported 
drinking 8 to 14 units of alcohol a week. Drinking above 
21 units a week increases total mortality [57]. Differences 
between types and patterns of alcohol intake remain unclear [58].
Diabetes mellitus Mortality from CHD increases about 3-fold to 10-fold and 2-fold 
to 4-fold in patients with type 1 and type 2 diabetes, respectively [49]. 
The UKPDS study indicated that for each increment of 1% increase 
in HbA1c there was a 1.11-fold increase in the risk of CHD [59].
Blood pressure Chronic hypertension is closely related to the risk of developing 
CHD [60]. A decrease of 5 mmHg in diastolic blood pressure is 
associated with a 21% decrease in risk of developing CHD [61].
Obesity Although increased body mass index is related to increased risk 
of CHD [62,63], there are no clinical trials of the effect of weight 
reduction on CHD morbidity and mortality [64].
CHD, coronary heart disease; UKPDS, UK Prospective Diabetes Study; HbA1c, glycated hemoglobin.Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 1 Pater
United States [68] and proposed as the common instru-
ment to guide treatment for raised blood pressure as well
as treatment with aspirin and statins [69,70].
The Framingham equations computed on the basis of pre-
specified categorical variables have been the mathemati-
cal background for calculation of absolute risk in the most
popular charts, tables and computer programs so far
[71,72]. However, it has been emphasized that the Fram-
ingham equations based on North American high-risk pop-
ulation may have limited applicability to other high-risk
groups, such as South Asians, Polynesians, African Ameri-
cans and South Europeans [73]. Evidence indicates that
risk prediction is quite reliable in central and western pop-
ulations [74,75], but is overestimated for southern popula-
tions [76,77].
Several methods are available at present for the assess-
ment of a patient’s risk of developing CHD. All of these
methods are based on estimates from the Framingham
study and they only take into account the standard risk
factors – gender, smoking, blood pressure, ratio of total
cholesterol to high-density lipoprotein cholesterol (HDL),
and presence of diabetes. Other factors such as family
history of premature CHD, ethnicity, obesity, and lifestyle
may need to be considered in clinical interpretation and
decision making in individual patients. The most commonly
used tools are the New Zealand Guidelines [78], the
Sheffield Table [79], and the Joint British Societies coro-
nary prediction chart [80].
The Sheffield table has been used to identify those
patients where measurements of total cholesterol and
HDL cholesterol are indicated. The modified Sheffield
table requires only yes/no categorization of the patient as
hypertensive, rather than a systolic blood pressure mea-
surement [79]. The Joint British Societies chart requires
more information and is not intended for use in treated
hypertensive patients. In these patients, the use of current
blood pressure measurements gives an underestimate of
risk. None of the charts are used in patients who already
have a diagnosis of CHD.
The Joint European societies have used the multiple-risk
approach to develop figures that allow the visual calcula-
tion of previous absolute risk of developing CHD over the
next 10 years, based on age, sex, smoking, systolic blood
pressure, and total cholesterol level [81] (Figs 6 and 7).
Cardiovascular risk is defined as the CHD risk plus the
risk of stroke, vascular disease and heart failure. Cardio-
vascular risk can be estimated from the CHD risk since
the two are correlated; a CHD risk of 15% equates to a
cardiovascular risk of 20% [81].
Figure 2
Cholesterol distribution and its shift (dashed line) with application of
population approach. Data from Carleton et al [95].
Figure 3
Prevalence distribution (bars) of serum cholesterol concentration
related to age-adjusted mortality from coronary heart disease (CHD)
(broken curve) in men aged 40–59 years. The number above each bar
is the percentage of death “attributable” to the cholesterol effect and
arising at that level. Data from Martin et al [96].
Figure 4
A conceptual framework for public health practice in cardiovascular
disease prevention.Identification of individuals at high absolute risk is straight-
forward and can be undertaken accurately by using one of
the available modalities mentioned above [17,83–85].
Quantification of the absolute risk assists in deciding upon
the need for lipid lowering treatment, considered at
present to decrease the risk of heart attacks and strokes
without increasing other causes of mortality or morbidity.
However, the increased understanding and widespread
Available online http://cvm.controlled-trials.com/content/2/1/024
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Table 3
Guide to primary prevention of cardiovascular disease
Risk intervention Recommendations
Smoking: Ask about smoking status as part of routine evaluation. Reinforce smoking status.
Goal Strongly encourage patient and family to stop smoking.
complete cessation Provide counseling, nicotine replacement, and formal cessation programs as appropriate.
Blood presure control: Measure blood pressure in all adults at least every 2.5 years.
Goal Promote lifestyle modification: weight control, physical activity, moderation in alcohol intake, and moderate 
<140/90 mmHg sodium restriction.
If blood pressure >140/90 mmHg after 3 months of life habit modigfication of if initial blood pressure 
>160/100 mmHg: add blood pressure medication, individualize therapy to patients`s other requirements 
and characteristics.
Cholesterol management: Ask about dietary habits as part of routine evaluation.
Primary goal Measure total and HDL cholesterol in all adults >19 years and assess positive and negative risk factors every 5 years.
LDL <160 mg/dl For all persons: promote AHA Step I diet (£30% fat, <10% saturated fat, <300 mg/day cholesterol), weight 
if 0–1 risk factors control, and physical activity.
or Measure LDL if total cholesterol ³240 mg/dl or ³200 mg/dl with ³2 risk factors or if HDl <35 mg/dl.
LDL <130 mg/dl If LDL Risk factors: age (men >45 years, women >55 years) 
if ³2 risk factors ³160 mg/dl with 0–1 risk factors or or postmenopausal), hypertension, diabetes, smoking, 
Secondary goals ³130 mg/dl on 2 occasions with ³2 risk factors;  HDL<35 mg/dl, family history of CHD in first-degree 
HDL >35 mg/dl; then Start Step II Diet (£30% fat,  relatives <65 years) HDL ³60 mg/dl: 
TG <200 mg/dl <7% saturated fat, <200 mg/dl cholesterol)  Substract 1 risk factor from the number of risk factors.
and weight control.
Rule out secondary causes of high LDL 
(LFTs, TFTs, UA).
If LDL:
³160 mg/dl plus two risk factors; or 
³190 mg/dl; or 
³220 mg/dl in men <35 years; or in premenopausal 
women; then consider adding drug therapy to 
diet therapy for LDL levels > those listed above 
that persist despite Step II Diet.
Suggested drug therapy for high LDL levels (³160 mg/dl) 
drug selection priority modified according to TG level) 
TG <200 mg/dl TG mg/dl 200–400 TG >400 mg/dl HDL <35 mg/dl: Emphasize weight management, 
physical activity, avoidance of 
cigarette smoking. Niacin raises HDL. 
Statin Statin Consider combined  Consider niacin if patient has ³2 risk 
Resin Niacin drug (niacin, therapy,  factors and high LDL (except patients 
Niacin fibrates, statin) with diabetes).
If LDL goal not achieved, consider combination drug therapy
Physcial activity: Ask about physical activity status and exercise habits as part of routine evaluation. 
Goal Encourage 30 min of moderate-intensity dynamic exercise 3–4 times per week as well as increased physical 
Increase amount of activity in daily life habits for persons who are active. 
exercise regularly Encourage regular exercise to improve conditioning and optimize fitness level.
3–4 times per week Advise medically supervised programs for those with functional capacity and/or comorbidities. 
for 30 min Promote environmental factors conducive to health (eg golf courses that permit walking).
Weight management: Measure patient`s weight and height, BMI, and waist-to-hip ratio at each visit as part of routine evaluation.
Goal Start weight management and physical activity as appropriate. Desirable BMI range 21–25 kg/m². BMI of 
Achieve and maintain 25 kg/m² corresponds to percentage desirable body weight of 110%; desirable waist-to-hip ratio for men, 
desirable BMI <0.9; for middle-aged and elderly women, <0.8).
(21–25 kg/m²)
BMI, body mass index; LDL = low-density lipoprotein; LFT, liver function test; TG, triglycerides; UA, uric acid; TFT, thyroid function test. Data from
Grundy et al [93].acceptance of the usefulness of lipid lowering treatment
has brought into consideration the cost-effectiveness of
such treatment. Current UK policy, for instance, recom-
mends that lipid lowering treatment should be offered to
anyone with an absolute annual risk of 3% or more [86],
while others favor a 1.5–2% absolute risk threshold before
beginning treatment [81,83]. Still others have argued that
estimates of relative risk should form the basis for treat-
ment guidelines [87]. Since age is the major determinant
of absolute risk, treatment thresholds based on absolute
risk will tend to postpone treatment to older age, whereas
guidelines based on relative risk will tend to lead to treat-
ment of younger people.
Using absolute risk for decision making on lipid lowering
treatment raises the problem faced by practicing clinicians
of what advice to give to younger people who are at sub-
stantially increased risk compared with their age group,
but who nevertheless remain below the defined absolute
risk threshold for treatment.
Common sense, of course, dictates that all such individuals
should be offered appropriate advice on lifestyle modifica-
tion at the earliest opportunity and that individualized deci-
sions about treatment should be taken from case to case,
based on the global risk profile of the particular individual.
Conclusion
Primary prevention programs aimed at reduction of risk
behaviors on a population-wide basis and the identification,
stratification, and selected treatment of high-risk individuals
prior to their development of disease should be corner-
stones of any approach to reduce the population’s burden
of CHD. Also, prevention strategies should begin in child-
hood. These two approaches should be complementary.
The healthcare system should benefit from population-
wide efforts via health education, environmental interven-
tion, or legislation to reduce the burden of deleterious
health behaviors. This should facilitate risk-factor change
in the clinical setting. Policy makers, employers, and com-
Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 1 Pater
Figure 5
Preventive strategies in CHD. A holistic approach to quantitative assessment.Available online http://cvm.controlled-trials.com/content/2/1/024
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Figure 6
Coronary risk chart for primary CHD prevention in men.Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 1 Pater
Figure 7
Coronary risk chart for primary CHD prevention in women.munity leaders look to healthcare providers to provide
advice and leadership. Both the capacity to prevent CHD
and the will to implement policies and programs will be
necessary to reduce CHD and communities and physi-
cians` offices [88].
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